Axitinib: Clinical Trials

14 trials of Axitinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 recruiting, 2 active not recruiting, 1 terminated. 14 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 7, Recruiting 3, Active not recruiting 2, Terminated 1, Unknown 1
Phase 23Completed 2, Unknown 1

Follow Axitinib: new trials by email Literature Review of Axitinib trials Research Report on Axitinib

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Phase 3RecruitingSWOG Cancer Research Network7182026-06-052026-06-11
CARE1 Pragmatic Clinical Trial
Nivolumab, Ipilimumab, Pembrolizumab - Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
Phase 3RecruitingGustave Roussy, Cancer Campus, Grand Paris12502024-04-122025-01-16
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
OTX-TKI (axitinib implant), Aflibercept - Neovascular Age-Related Macular Degeneration
Phase 3Active not recruitingOcular Therapeutix, Inc.3442024-01-292025-04-18
The Efficacy and Safety of KN046 Combined With Axitinib
KN046 plus Axitinib - NSCLC
Phase 2 / Phase 3UnknownShanghai Pulmonary Hospital, Shanghai, China202023-08-252023-08-31
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Axitinib plus Toripalimab, nephrectomy - Renal Cell Carcinoma, Neoadjuvant
Phase 3RecruitingZHOU FANGJIAN2982023-04-192026-03-17
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
fruquintinib+sintilimab, axitinib / everolimus, fruquintinib - Advanced Renal Cell Carcinoma
Phase 2 / Phase 3CompletedHutchmed2652022-10-272026-10-20
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Avelumab, Lorlatanib, Talazoparib - Advanced Malignancies, NSCLC
Phase 3Active not recruitingPfizer772021-09-292026-10-20
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Pembrolizumab, Axitinib, Sunitinib - Renal Cell Carcinoma
Phase 3CompletedMerck Sharp & Dohme LLC8612016-09-162026-02-02
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib - Renal Cell Cancer
Phase 3CompletedPfizer8862016-03-232025-07-30
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Axitinib, Placebo - Clear Cell Renal Carcinoma
Phase 3TerminatedSFJ Pharma Ltd. II7242012-04-012019-09-20
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Axitinib, Sandostatin LAR, Placebo - Neuroendocrine Tumors, Advanced Cancer
Phase 2 / Phase 3CompletedGrupo Espanol de Tumores Neuroendocrinos2562011-11-012026-04-28
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Axitinib (AG-013736), Sorafenib - Kidney Neoplasms
Phase 3CompletedPfizer4922009-08-252022-05-06
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Axitinib (AG-013736), Sorafenib - Kidney Neoplasms
Phase 3CompletedPfizer7232008-09-032019-01-09
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
AG-013736, Gemcitabine, placebo - Carcinoma, Pancreatic Ductal
Phase 3CompletedPfizer6302007-07-012012-07-16

Conditions studied

Carcinoma, Renal Cell (6)  ·  Kidney Neoplasms (4)  ·  Carcinoma, Pancreatic Ductal (1)  ·  Clear-cell metastatic renal cell carcinoma (1)  ·  Kidney Diseases (1)  ·  Neoplasms (1)  ·  Neuroendocrine Tumors (1)  ·  Ovarian Neoplasms (1)

Sponsors

Pfizer (5)  ·  Grupo Espanol de Tumores Neuroendocrinos (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Hutchmed (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Ocular Therapeutix, Inc. (1)  ·  SFJ Pharma Ltd. II (1)  ·  SWOG Cancer Research Network (1)  ·  Shanghai Pulmonary Hospital, Shanghai, China (1)  ·  ZHOU FANGJIAN (1)

Countries

United States (8)  ·  China (6)  ·  France (6)  ·  Spain (6)  ·  Italy (5)  ·  Japan (5)  ·  Russia (5)  ·  South Korea (5)  ·  Taiwan (5)  ·  United Kingdom (5)  ·  Australia (4)  ·  Austria (4)  ·  Canada (4)  ·  Germany (4)  ·  India (4)

Top investigators

Dingwei Ye (1)  ·  Fangjian Zhou, Professor (1)  ·  Pedro Barata (1)  ·  Rocio Garcia Carbonero, MD (1)  ·  Zhi Song He (1)

Results publications

PMID 37526095, PMID 33947608, PMID 37146227, PMID 27238653, PMID 28410911, PMID 21306953, PMID 22056247, PMID 23579211, PMID 23598172, PMID 23630366, PMID 24206640, PMID 24823696, PMID 25577718, PMID 26089686, PMID 27498023, PMID 29439857, PMID 30346481, PMID 30779529, PMID 30779531, PMID 31072748, PMID 32339648, PMID 32363929, PMID 32895571, PMID 33152282, PMID 33284113, PMID 33901870, PMID 34244116, PMID 35166465, PMID 35239416, PMID 35843776, PMID 37104931, PMID 37852850, PMID 39706335, PMID 39815637, PMID 39886142, PMID 40750932, PMID 41719493

NIH funding

2023 (3), 2008 (1), 2015 (1), 2016 (1), U10CA180888 (1)